The Minister for Covid Vaccine Deployment (Nadhim Zahawi)

- Hansard -

Copy Link

-

The lockdown has reduced social contact and, as such, the numbers of covid-19 cases, hospital admissions and death rates have reduced significantly but continue to remain high across the country. As of 25 February, the weekly case rate for all ages in England is on average 97.1 per 100,000, and 65.2 per 100,000 for people aged 60 and over. Overall positivity for England is 4.3%, with rates continuing to remain higher than desired across the whole country. These figures remain high indicating that we are not yet ready to ease further restrictions immediately from an epidemiological perspective.

Data indicates that the number of patients in hospital with covid-19 across England has reduced to 10,765 and mechanical ventilation bed occupancy is 1,658 (as of 1 March). Sadly, between 15 February and 21 February there have been a total of 2,421 covid-19 related deaths in England, within 28 days of a positive covid-19 test. The number of deaths within 28 days of a positive test has fallen and now reflect levels seen at the end of October. The coronavirus England briefing, 4 March 2021, is available here:

https://www.gov.uk/government/publications/coronavirus-england-briefing-4-march-2021

The vaccine rollout continues to be a success for the UK. As of 2 March, over 20.4 million people across the UK have now received their first dose of a covid vaccine—equal to over a third of the adult population, and over 840,000 people have now received their second dose of a covid vaccine. Daily updates on vaccines doses are available here:

https://coronavirus.data.gov.uk/details/vaccinations

On 22 February, the Prime Minister announced a four-step roadmap to move England out of the current national lockdown. The Government will take a cautious approach to easing restrictions which is guided by data. The measures set out for 8 March prioritise the return of face-to-face education in schools and colleges.

The full roadmap publication can be found at the following link: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963491/COVID-19_Response_-_Spring_2021.pdf

Progression to the next step of the roadmap will be guided by data, and not dates. There will be at least five weeks between the steps in the roadmap: four weeks for the data to show the impact of the previous easing; and one week’s notice for the public and businesses ahead of future changes.

Before taking each step, the Government will review the latest data on the impact of the previous step against four tests.

1. The vaccine deployment programme continues successfully

2. Evidence shows vaccines are sufficiently effective in reducing hospitalisations and deaths in those vaccinated.

3. Infection rates do not risk a surge in hospitalisations which would put unsustainable pressure on the NHS

4. Our assessment of the risks is not fundamentally changed by new variants of concern.

[HCWS825]

The Parliamentary Under-Secretary of State for Health and Social Care (Nadhim Zahawi)

- Hansard -

Copy Link

-

With permission, I would like to make a statement on coronavirus, but before I do that I wish my shadow opposite number, the hon. Member for Nottingham North (Alex Norris), a happy birthday.

Our nation is getting safer every day as more and more people get protected by the biggest immunisation programme in the history of our health service. More than 10 million people have now received their first dose of one of our coronavirus vaccines. That is almost one in five adults in the United Kingdom. We are vaccinating at scale, while at the same time retaining a close focus on the most vulnerable in our society to make sure those at greater need are at the front of the queue.

I am pleased to inform the House that in the UK we have now vaccinated almost nine in 10 over-80s, almost nine in 10 over-75s and more than half of people in their 70s. We have also visited every eligible care home possible with older residents in England and offered vaccinations to all their residents and staff. That means we are currently on track to meet our target of offering a vaccine to the four most vulnerable groups by mid-February.

That is an incredible effort that has drawn on the hard work of so many, and I want to just take a moment to thank every single person who has made this happen: the hundreds of thousands of volunteers up and down the country, the scientists, our colleagues in the NHS—the GPs, the doctors, the nurses and the vaccinators—those in social care, the manufacturers, the local authorities, the armed forces, the civil servants who work night and day to make this deployment possible, and anyone else who has played a part in this hugely logistical endeavour. It really is a combination of the best of the United Kingdom. At our time of national need, you have given us a big boost in our fight against this deadly virus, which remains a big threat to us all.

There are still more than 32,000 covid patients in hospital, and the level of infection is still alarmingly high, so we must all stay vigilant and keep our resolve while we keep expanding our vaccination programme, so that we can get more people protected even more quickly. We have an ambitious plan to do that. We are boosting our supply of vaccines and our portfolio now stands at more than 400 million doses, some of which will be manufactured in the United Kingdom, and we are opening more vaccination sites, too. I am pleased to inform the House that 39 new sites have opened their doors this week, along with 62 more pharmacy-led sites. That includes a church in Worcester, Selhurst Park—the home of Crystal Palace football club—and a fire station in Basingstoke, supported by firefighters and support staff from Hampshire Fire and Rescue Service.

One of the greatest pleasures for me over the past few months has been seeing the wide range of vaccination sites that have been set up right in the heart of our local communities. Cinemas, mosques, food courts and so many other institutions have now been transformed into life-saving facilities, giving hope to people every day. Thanks to that rapid expansion, we have now established major national infrastructure. There are now 89 large vaccination centres and 194 sites run by high street pharmacies, along with 1,000 GP-led services and more than 250 hospital hubs. Today’s announcement will mean that even more people will live close to a major vaccination site, so we can make vaccinating the most vulnerable even quicker and even simpler.

We have always believed in the power of science and ingenuity to get us through this crisis, and I was pleased earlier this week to see compelling findings in The Lancet medical journal, reinforcing the effectiveness of our Oxford-AstraZeneca vaccine. It showed that the vaccine provides sustained protection of 76% during the 12-week interval between the first and second dose, and that the vaccine seems likely to reduce transmission to others by two thirds. That is really great news for us all, but we will not rest on our laurels.

No one is really safe until the whole world is safe. Our scientific pioneers will keep innovating, so that we can help the whole world in our collective fight against this virus. I saw how wonderful and powerful this ingenuity could be when I was one of thousands of volunteers who took part in the Novavax clinical trial, which published very promising results a few days ago. Today, I am pleased to announce another clinical trial—a world-first study that will help to cement the UK’s position as a global hub for vaccination research. This trial will look at whether different vaccines can be safely used for a two-dose regime in the future to support a more flexible programme of immunisation. I want to reinforce that this is a year-long study, and there are no current plans to change our existing vaccination programme, which will continue to use the same doses. But it will perform a vital role, helping the world to understand whether different vaccines can be safely used. Our scientists have played a pivotal part in our response to this deadly virus, and once again they are leading the way, helping us to learn more about this virus and how we should respond.

It has been heart-warming to see how excited so many people have been to get their vaccine and to see the work taking place in local communities to encourage people to come forward to get their jab. Hon. Members have an important role to play too. I was heartened to see colleagues from both sides of the House coming together to encourage take-up within minority ethnic communities through two joint videos posted on social media last week. As the video rightly says, “MPs don’t agree all the time, but on taking the vaccination, we do.” I could not agree more, and I am grateful to every single Member who has come forward to support this national effort. We want to make it as easy as possible for colleagues to do so. This week, we published a new resource for Members that provides more information on the vaccine roll-out and what colleagues can do to increase the take-up of the vaccine in their constituencies. That is an extremely valuable resource, and I urge all Members to take a look at it and think about what they can do in their constituencies.

Our vaccination programme is our way out of this pandemic. Even though the programme is accelerating rapidly and, as the chief medical officer said yesterday, we appear to be past the peak, this remains a deadly virus, and it will take time for the impact of vaccinations to be felt. So for now, we must all stand firm and keep following the steps that we know make a big difference until the science can make us safe. I commend this statement to the House.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to the hon. Gentleman for his constructive way of engaging with the vaccination deployment programme. On trials, we have two running currently, both with Public Health England. The Vivaldi trial is testing residents of care homes, who were in category 1 of the JCVI categories. The second is Siren, which is testing frontline health workers, who are in category 2. As Jonathan Van-Tam, the deputy chief medical officer, has said, we will know the infection and transmission data from those trials in the next few weeks. Of course, the Oxford data is very promising—it needs to be peer reviewed—but those trials will also capture the Oxford vaccine, because obviously that came on site in January.

On the priority list, the JCVI looked very closely at both black, Asian and minority ethnic and, of course, other considerations, including by profession, and came down clearly on the side of age as the deciding factor in people’s risk of dying from covid. This is a race against death, hence the nine categories, which we are going through, and we will continue to do so. A number of professions will be captured in those categories. Of course, those with extremely severe illness will be captured in the category for the severely extremely vulnerable, and others will be captured in further categories down the phase 1 list.

I certainly think it would be wrong to change the JCVI recommendation, because categories 1 to 9 account for 99% of mortality. When we get into phase 2, we would welcome a debate and, of course, will ask the JCVI about including professions such as teachers, shop workers and police officers, who through their work come into contact with much greater volumes of the virus than others do, and it will advise us accordingly.

On BAME and ethnicity, the NHS now collects such data, and we are publishing it. We are doing an enormous amount of work not only across Government, but with the NHS, to ensure that we bring in local government so that we can begin to share data. I would welcome us working much closer with local government and the NHS so that we can identify, to the individual level, the people we need to protect as soon as possible.

I put it on the record that I want clinical commissioning groups to share data with MPs. Several colleagues—[Interruption.] Including you, Madam Deputy Speaker; I can see you nodding away vigorously. CCGs should and must engage with local politicians, because MPs get a lot of emails and telephone calls from concerned constituents in the top four most vulnerable categories. Of course, the NHS has plans to publish CCG-level data very soon.

As for care home staff, we had a fantastic response through the care home vaccination programme, which is category 1, and we continue to do more with staff to encourage them to be vaccinated, because we make four visits into care homes. Visit one is for the first dose, visit two is to try to vaccinate those who may have been infected the first time, because people cannot be vaccinated until after 28 days, visit three will be for second doses, and so on. We are getting greater traction with care home staff, but the hon. Gentleman is right to mention that. There is a big focus on helping them to go to hospital hubs and, of course, their primary care networks.

On the second dose, everyone who has had a first dose of Pfizer will get a second dose of Pfizer within that 12-week dosing period. That will begin in March in the usual way that the NHS does vaccinations. Everyone who has had a first dose of Oxford-AstraZeneca will get a second dose of Oxford-AstraZeneca within 12 weeks as well.

The hg is right to ask about people wanting the option of going either to a national vaccination centre or to the PCN. If right hon. and hon. Members have particular cases, please point them to us and we will do everything we can to ensure that that is facilitated.

The hon. Gentleman rightly highlighted HIV clinics. I will take that matter away and see whether there is a workaround for those who want to have that information remain private from their GP. We will see what we can do.

This is World Cancer Day, and there is now real excitement in the scientific community in the UK about the messenger RNA vaccine, because people can begin to think about vaccines for cancers as well. However, the hon. Gentleman raises an important point about those who care for the clinically extremely vulnerable, and we want to ensure that we deliver the JCVI phase 1 and then very quickly reach the rest of the population.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to the Chair of the Health and Social Care Committee for his question, and he is absolutely right. The manufacturers are already working on variants to their vaccine to take into account the mutation of the virus. Viruses will mutate to survive and this virus is no different. There are about 4,000 mutations now around the world, some more concerning than others. We have, in the United Kingdom, a genome sequencing industry that is a world leader—about 50%, or just under, of the sequencing has taken place in the United Kingdom. Not only are we working with the current manufacturers—Pfizer-BioNTech, AstraZeneca and Moderna —that have been approved, but we are also looking at how we can make sure that we make the most of the new messenger RNA technology, which allows the rapid development of vaccine variants that will then deal with the virus variants as rapidly as possible. When I spoke to the Science and Technology Committee a few weeks ago, I said that we were planning to have in place the ability to go from the moment that we can sequence a variant that we are really concerned about to the moment that we can have a vaccine ready in between 30 to 40 days, with then, of course, the manufacturing time.

We have invested in Oxfordshire, in the Vaccines Manufacturing and Innovation Centre, and in the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in Braintree—£127 million there and just shy of £100 million in Oxfordshire—to be ready to manufacture any vaccine that we would need. The Prime Minister, of course, also visited those making what I refer to as our seventh vaccine, the Valneva vaccine. That is a whole inactivated virus, so it does not just work on the spikes in the way that the two current vaccines that we are deploying work. It works on the whole of the virus, which is much more likely to capture any mutations from the spikes and therefore be incredibly effective. We have invested in that production facility in Scotland so that we can have that vaccine as a future-proofing of annual vaccination strategies or a booster in the autumn, if necessary.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for the hon. Member’s question, albeit, dare I say, I do not recognise his description of our collaboration. We have, over the past two weeks, been working solidly. The British Army—the armed forces—have been working to deliver 80 vaccination sites in Scotland and to hand them over to NHS Scotland within 28 days, and that work began a couple of weeks ago. So I hope he recognises the effort the United Kingdom is putting in not just in supplying the vaccines for Scotland, Wales, Northern Ireland and England, but in the way we are trying to support the vaccine deployment in Scotland.

Of course, last weekend was our target to make sure that every eligible care home in England was visited, and over 10,000 care homes have actually been visited and received the vaccine. Only a handful of care homes, which were deemed to have an outbreak, were not visited. The NHS, quite rightly, celebrated achieving that target last weekend, so I am slightly saddened, in a way, that there is this politicking between ourselves about this issue.

We continue—as the shadow Minister, the hon. Member for Nottingham North (Alex Norris), asked me—to work very hard to make sure that staff in care homes are also offered the vaccine on those visits, and they also have an opportunity to be vaccinated in their primary care networks and, of course, in hospitals.

On the JCVI, those who are clinically extremely vulnerable are in category 4, and we will vaccinate them by mid-February.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for my hon. Friend’s question. I certainly join her in thanking the teams that have been working and delivering in North Lincolnshire. These are extraordinary people doing really incredible work, and I want to thank them from the bottom of my heart.

We try as hard as we can in the team to make sure we give as much notice as possible to local teams about when they are getting their delivery. This week, yesterday—Wednesday—everyone would have had notice of their deliveries for next week. We want to give as much notice as possible. Our limiting factor remains vaccine supply. It is becoming more stable, and we have greater visibility of vaccines all the way through to March, hence our confidence about meeting our targets. I can reassure my hon. Friend that her local teams will get the vaccines they need to meet the mid-February target of vaccinating the top four cohorts and protecting them before that date.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for the hon. Lady’s question. It is great to hear about the Harlequins joining the fight, as they always do, when it comes to the United Kingdom actually getting people protected and vaccinated.

Care home and domiciliary staff are both on our priority list, as the hon. Lady knows. We are working with local government, and David Pearson, who is of course a champion of the social care sector, has been working with local government to identify them. The best way to identify domiciliary staff is through local government, because a lot of people will be with agencies and, as the hon. Lady quite rightly pointed out, are hard to reach. They are in our target: they are part of the top four categories, with those who are caring for the elderly in residential care homes, and we will meet our target of offering them a vaccine by mid-February.

Nadhim Zahawi

- Hansard -

Copy Link

-

I want to reassure my hon. Friend that, through the vaccines taskforce, we have been liaising extensively with the vaccines’ developers and the related organisations to ensure that the highest level of security exists through the whole vaccine deployment chain. That has, of course, included working directly with the manufacturers, and we have a senior responsible officer seconded to the team to make sure that security is at the forefront of everything we do to deliver this programme. We cannot allow a lapse of security to get in the way of the largest vaccination programme in the history of this country.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to the hon. Gentleman for raising this issue. It is a priority for us and we will be saying more on it very soon, because the groups who have not received the letters but are shielding remain incredibly important. He is absolutely right to raise the issue, which is a priority for us.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to my hon. Friend for her question. I am delighted to see that in her constituency the vaccination programme has rolled out so efficiently and well. She is right to point out the issue of choice; we deliberately wanted people to have the choice to be able to go to a vaccination centre or to go through their primary care networks or hospital hub. I will make sure that each and every person in those four categories is offered a vaccine. We have a strategy, which we are now implementing because we are so close to that deadline, of reaching out to the granular level—to GPs—to go through exactly the population in each of those four categories, in order to make sure we know that everybody has been reached and offered that vaccine. I just give her that reassurance.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for the hon. Lady’s question. Community and independent pharmacies have a significant role to play; she may have heard me refer earlier to the hundreds that are already in the programme, delivering vaccines. The reason for the 1,000 vaccinations a week minimum is that, when vaccine supply is finite and every dose matters, we cannot afford for vaccines to just sit in a fridge in a smaller pharmacy. As vaccine supply begins to improve, we can look at bringing in more pharmacies. At the moment, 98% of the country is within 10 miles of a vaccination site; for the 2%, we will go to them with a pop-up site. I want us to get to a stage, once we have done phase 1, where we are maybe able to be more convenient and where people can pop into their local pharmacy once supply allows.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to my hon. Friend for his question. Pfizer itself says that it is up to the national regulatory authority to advise on the dosing interval. Not only the Medicines and Healthcare products Regulatory Agency—which is our regulator—but the Joint Committee on Vaccination and Immunisation and the four chief medical officers of England, Scotland, Wales and Northern Ireland all agreed that the up to 12-week interval for Pfizer-BioNTech is exactly the right thing to do to make sure we protect as many people as possible. They cited Pfizer’s own data that, after 15 days, up to 21 days, protection is up to 89% with the first dose.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for the hon. Gentleman’s question, and I will certainly look at that specific example, if he is able to give me the details. The data that will be published at 2 pm for his sustainability and transformation partnership will show that vaccination levels for the over-80s are now over 75%, which is an improvement, but they need to go even further, so I will happily take a look at that. Of course, the recent large vaccination site opened at Network House, Wembley will also help with that.

Nadhim Zahawi

- Hansard -

Copy Link

-

I agree with my hon. Friend. The fantastic NHS staff have stepped up in the most challenging of circumstances, and it is imperative that they are part of this first phase of the vaccination programme.

A significant milestone was achieved last week, as my hon. Friend will have heard me say earlier: we have now gone into every eligible care home of older adults to offer their staff and residents their first dose of the vaccine. This is testament to our remarkable care home staff and NHS workers. I urge all social care and front- line health care workers to take up the vaccine when it is offered to them. The recent large vaccination centre for my hon. Friend’s constituency is the Spectrum Community Health CIC in Wakefield, which staff can also access. We continue to make progress with staff, and our aim is to offer to each and every member of staff that vaccination by the middle of February.

Nadhim Zahawi

- Hansard -

Copy Link

-

The hon. Lady raises an important point. The vaccines that we are currently deploying will work on the variants that are in the United Kingdom. Both the deputy chief medical officer, Jonathan Van-Tam, and the chief scientific adviser have said that they would be very surprised if the current vaccines have no impact on the variants of the virus, so we continue to vaccinate at speed, at the same time, of course, as being vigilant by sequencing the new variants. Of course, we are able to react, with the manufacturers, to any future need in respect of the vaccination programme. At the moment, the vaccines are exactly the right thing to do, including because of the protection against severe infection and hospitalisation that they offer, which remains incredibly high with both vaccines.

Nadhim Zahawi

- Hansard -

Copy Link

-

My hon. Friend and I have had conversations about this matter because he is a great champion of his constituents. He will be aware that there has been a huge amount of work to step up vaccination services in Medway in recent weeks. Each primary care network site receives its own supply, and work has been carried out with the local CCG to ensure that the vaccine supply aligns with the number of registered patients in the priority cohort groups—groups 1 to 4. When some sites progress through their supply more quickly than others, we work with them to ensure that supplies are replenished as quickly as possible so that they can continue to vaccinate the most vulnerable. We are keeping a close watch on my hon. Friend’s area because, as he quite rightly points out, it has gone through some difficulties. I reassure him that the latest numbers I have for the Kent and Medway STP show that 86.3% of over-80s have had the first dose.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for the hon. Member’s question, although I am slightly surprised because it is the United Kingdom’s armed forces and the United Kingdom’s vaccine that are being deployed, and I hope we can celebrate that. [Interruption.] I see the hon. Member for Nottingham North (Alex Norris) nodding across the Dispatch Box—and I think he is smiling underneath that mask as well.

Nadhim Zahawi

- Hansard -

Copy Link

-

I add my thanks to those of my hon. Friend for the relentless determination of her excellent local PCNs to vaccinate the most vulnerable. I would be very happy to meet colleagues to go through in detail the plan up to mid-February, which is our target, and beyond. I am also happy to take away her PCNs’ specific concern about data sharing. Our mantra in the team is to make as much data available as quickly as possible, when we know that it is robust and actionable, so we will look at her point about Foundry and Outcomes4Health to ensure that we can share that. I want to get to a stage where every PCN can track its order, in the way we track an order from Amazon. We have reached basecamp, but we have a big climb ahead of us to vaccinate the whole nation.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to the hon. Lady for that incredibly important question. Her region has done phenomenally well. I want to praise it because it has 91.8% of first doses for the over-80s in the STP. The NHS is already sharing data with local government. We need to make it more granular. We have brought into the deployment campaign Eleanor Kelly, the former chief executive of Southwark Council, so we are totally in line and integrated with local government, because they know exactly where those hard-to-reach groups are. The hon. Lady raises an incredibly important point and that is a big focus for me.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to my right hon. Friend for his excellent question. My absolutely priority is to ensure that we have the inventory—as he quite rightly describes it—to allow us to offer the vaccine to all adults in the United Kingdom, and at the moment we are nowhere near that. Supply remains the limiting factor in our first target, which is to vaccinate groups 1 to 4 by mid-February, and then groups 5 to 9 as soon as we can after that, with phase 2, which we have been discussing today, after that. He is absolutely right that we have now ordered or optioned 407 million doses of vaccine. Once we are in a position to secure enough vaccine for the United Kingdom’s population, we will be able to look at where else we can help with our vaccine supply. We have also put £1.3 billion into a combination of Gavi, the Vaccine Alliance, and COVAX. Of that £1.3 billion, approximately £480 million is going to COVAX, which is helping low and middle-income countries with their vaccination programmes as we speak.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful and incredibly encouraged by the hon. Gentleman’s brilliant initiative, taken with many colleagues across the House, to deliver that brilliant video of south Asian MPs from different political backgrounds and traditions all recommending that, when people’s turn comes, they should take the vaccine.

We have been working across Government. In the Cabinet Office, the covid disinformation unit was set up in March. It works online with the digital platforms to ensure that we identify disinformation and misinformation to them. They should be taking that down immediately. My message to all of them, whether Twitter, Facebook or any of them is this: “You must, must be responsible and play your part in taking this disinformation down as soon as we flag it up to you.”

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to my hon. Friend for his question. I will certainly join him in thanking the NHS family and army of volunteers. They have done phenomenally well. I can tell him that in his STP in Gloucestershire, 94% of the over-80s have received their first dose—that is pretty good going. He will know that we have built a deployment infrastructure than can deploy as much vaccine supply as we are able to bring in. A couple of Saturdays ago, we reached a record of just shy of 600,000 doses in a single day. That is, I guess, a demonstration of the capability of the infrastructure. We continue to grow it, as I announced today. It is very much dependent on vaccine supply. We have good visibility from here to the end of March, with more volume coming through beyond that. My focus should—I hope he agrees—be on the mid-February deadline to vaccinate those top four cohorts of the most vulnerable. That is 88% of mortality and, if we can get them done by mid-February, we will have achieved a real milestone in our fight against this virus.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to the hon. Gentleman for his question. The primary care networks have done a fantastic job in delivering the vaccine roll-out and will continue do so as we go beyond the first four cohorts into cohorts 5, 6, 7, 8 and 9 and then the next phase. Of course we want to make sure that people have choice. He will know by 2 pm, I think—when the next set of data is published—that his STP has reached 89% of the over-80s, which is an incredible achievement, the bulk of which has been done by the primary care networks. We will continue to support those networks. Through him, I send my thanks and appreciation to them and say that we will redouble our efforts to make sure that they get the vaccine doses that they need to get through not just the first four cohorts, but beyond that to the deployment programme for groups 5, 6, 7, 8 and 9.

Nadhim Zahawi

- Hansard -

Copy Link

-

There is no one who wants to see the economy open and functioning as soon as possible more than my right hon. Friend and the Prime Minister. As my right hon. Friend the Member for Forest of Dean (Mr Harper) rightly points out, the deadline for the top four cohorts is the middle of February. If we go forward three weeks from there, that is when the protection of the two vaccines really kicks in. The plan is to reopen schools on 8 March, after which we will gradually reopen the economy. It is important also to wait for the evidence. As I said earlier, the Vivaldi study and the SIREN study will enable us to see the impact of the vaccines on infection rates and on transmission. We are getting some really positive data from Israel and, of course, from the Oxford team. That will be our own robust evidence and, as the Prime Minister said, we will then share with the House on 22 February the roadmap of how we intend very gradually to reopen the economy.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to the hon. Lady for her question. We will do so in a couple of ways. First, once we have enough vaccine supply to be able to offer the vaccine to every adult in the United Kingdom—every eligible group from 1 to 9 and then phase 2—we will then look at our vaccine supply strategy. At the moment, we are nowhere near having enough supply to be able to make that offer. That has to be our priority. She mentions COVAX, but that is only part of the story for us in the United Kingdom. We have put about £450 million-plus into COVAX, but a total of £1.3 billion into the vaccine initiative of GAVI, the Vaccine Alliance. We are, I think, the largest donor, not only in money but per capita. We are making a big, big impact globally in both research and development, and vaccinations to low and middle-income countries.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for my hon. Friend’s congratulations. I stand on the shoulders of heroes; it is the army of the NHS family, volunteers and our armed forces that is doing the real heavy lifting in this deployment.

I visited Cullimore chemist in Edgware, a brilliant independent chemist that is delivering the vaccination programme. At the moment, the limiting factor is the ability to do 1,000 vaccine doses a week because of the finite amount of vaccine. However, as we get more volume through, I, like my hon. Friend, want to see convenience, so that someone can walk down the road to their local chemist. I look forward to doing that with him, I hope, one day.

Nadhim Zahawi

- Hansard -

Copy Link

-

The hon. Gentleman is absolutely right that we need to share as much granular data as possible with local public health officials and, of course, make sure that local government can target home by home, individual by individual, as soon as possible. I want to see the CCG-level data published, and the NHS will be doing that very soon. We continue to make sure that we work closely with local government to understand what additional data is needed, and I mentioned Eleanor Kelly joining the team from local government. That is exactly my intention, and the hon. Gentleman raises a really important question, because if we are going to target and reach the hard-to-reach groups in the BAME community, we need that information.

Nadhim Zahawi

- Hansard -

Copy Link

-

My right hon. Friend will appreciate the importance of maximising the vaccine available to GPs by using both the Pfizer vaccine and the Oxford-AstraZeneca vaccine, but in recent weeks the volume of Oxford-AstraZeneca going to GP sites has been higher than that of Pfizer, allowing the flex to visit the housebound and care homes and to deploy at individual practices in rural areas, as he rightly points out. Any site that wishes to discuss its vaccine allocations should do so with its local system in the first instance, and thereafter with the NHS regional team, but I am very happy to look at any specific examples.

Nadhim Zahawi

- Hansard -

Copy Link

-

I will keep it short, Madam Deputy Speaker. My target is mid-February for the top four cohorts. Either I or the Secretary of State will then come to the Dispatch Box to share with the House the plan beyond category 4, into categories 5, 6, 7, 8 and 9.

Nadhim Zahawi

- Hansard -

Copy Link

-

I will certainly join my hon. Friend in congratulating the Betsi Cadwaladr University Health Board, the GPs and their teams and the many volunteers. I can confirm that Wales and the Welsh NHS will have received the allocation for groups 1 to 4 by mid-February for them to be able to do that, and I commend them for the work they are doing.

Nadhim Zahawi

- Hansard -

Copy Link

-

We are absolutely looking to make sure that unpaid carers are on the priority list.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for my hon. Friend’s excellent, thoughtful suggestion. I will certainly take that away and discuss it with the Minister responsible in the Department.

The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (Nadhim Zahawi)

- Hansard -

Copy Link

-

May I add my congratulations to President Biden and Vice-President Kamala Harris, and their national security team?

I thank all hon. Members who have tabled amendments and new clauses and have spoken to them so eloquently: the hon. Member for Dundee East (Stewart Hosie); my right hon. Friend the Member for New Forest East (Dr Lewis); the shadow Minister, the hon. Member for Newcastle upon Tyne Central (Chi Onwurah); my hon. Friend the Member for Tonbridge and Malling (Tom Tugendhat); the hon. Member for Aberavon (Stephen Kinnock); the hon. Member for Caithness, Sutherland and Easter Ross (Jamie Stone), who spoke so pithily; my hon. Friend the Member for South Ribble (Katherine Fletcher); the right hon. Member for North Durham (Mr Jones); the hon. Member for Ilford South (Sam Tarry); my hon. Friend the Member for Arundel and South Downs (Andrew Griffith); the hon. Member for Strangford (Jim Shannon); my hon. Friend the Member for Isle of Wight (Bob Seely); the hon. Member for Liverpool, Riverside (Kim Johnson); my hon. Friend the Member for Beckenham (Bob Stewart); the hon. Member for Warwick and Leamington (Matt Western), my neighbour; and of course my right hon. Friend the Member for South Holland and The Deepings (Sir John Hayes), who reminded us of the words of the great Edmund Burke.

National security is an area of utmost importance, and that has been reflected in a sober and considered debate, with the excellent contributions that we have heard today, and, indeed, over the past few months. I will take this opportunity to respond to some of the points raised this afternoon.

New clauses 4 and 5 create a non-exhaustive list of factors that the Secretary of State must have regard to when assessing national security risks arising from trigger events. In fact, the Secretary of State has joined us to demonstrate how important this Bill is to him. I congratulate him on his elevation to being my new boss at BEIS.

As currently drafted, the Bill does not seek to define national security or include factors that the Secretary of State must or may take into account when assessing national security risks. Instead, factors that the Secretary of State expects to take into account when deciding whether to exercise the call-in power are proposed to be set out in the statement provided for by clause 3, a draft of which was published alongside the Bill. The Secretary of State is unable to call in an acquisition of control until that statement has been laid before both Houses. It is clear from the debate today, and also from conversations with colleagues, that these are the amendments on which there is strongest feeling in the House, and in the Foreign Affairs and Development Committee, so I will take care to set out the Government’s case.

The Bill’s approach reflects the long-standing policy of Governments of different hues to ensure that powers relating to national security are sufficiently flexible to address the myriad risks that may arise. As we heard from my hon. Friend the Member for Beckenham, national security risks are multi-faceted and constantly evolving, and what may constitute a risk today may not be a risk in the future. Indeed, the Foreign Affairs Committee, chaired by my hon. Friend the Member for Tonbridge and Malling, said in its own excellent report that

“an overly specific definition of national security could serve to limit the Government’s ability to protect UK businesses from unforeseen security risks.”

Nadhim Zahawi

- Hansard -

Copy Link

-

My hon. Friend makes an important point. As I mentioned, the statement that the Secretary of State has laid with the Bill takes in much of the direction of travel of this amendment from the Foreign Affairs Committee.

I acknowledge that the Foreign Affairs Committee is pushing for more detail rather than less, but I would reassure them that the Government agree with their main conclusion that the Secretary of State should provide as much detail as possible on the factors that will be taken into account when considering national security. Importantly, however, that is only up until the point that the detail risks the protection of national security itself. That is why the Government have taken this approach in the draft statement provided for by clause 3. In that statement, we identify three types of risk that are proposed to form the basis of the call-in national security assessment. These are: the target risk, which considers the nature of the acquisition and where it lies in the economy; the trigger event risk, which considers the level of control and how it might be used; and the acquirer risk, which covers the extent to which the acquirer raises national security concerns.

I would like to address each of the arguments made in the report, so that I can ease the concerns of hon. Members across the House. First, there are concerns that without a narrow definition of national security, the investment screening unit would be inundated by notifications, hampering its ability to deliver its crucial role. I acknowledge that, for business confidence in the regime, it is essential that we deliver on our statutory timeframes for decisions, which is why it is so essential that we do not allow any broadening of the assessment done by officials as part of the regime to occur, whether by inexhaustive lists, as my hon. Friend the Member for Isle of Wight has just said, or by any other form. To include modern slavery, genocide and tax evasion as factors that the Secretary of State must take into account as part of national security assessments, as these amendments propose, would not reduce the demands on the investment security unit but potentially increase them.

Secondly, there is concern that ambiguity could hinder the success of the regime. Let me be clear that this regime is about protecting national security—nothing more, nothing less—hence its real focus. Thirdly, the Foreign Affairs Committee report suggests that the staff responsible for screening transactions may lack sufficient clarity on what kinds of transactions represent legitimate national security risks, leading to important transactions being missed or to a large volume of benign transactions overwhelming the investment security unit. I want to assure hon. Members, and my hon. Friend the Chairman of the Foreign Affairs Committee, that the investment security unit will be staffed by the brightest and best, with many of them being recruited on the basis that they have essentially written the book on national security.

Nadhim Zahawi

- Hansard -

Copy Link

-

That is something I have been watching carefully as we introduced this legislation, obviously. We have had around 36 inquiries to the team already, so it feels to me that where we have landed is proportionate and right.

Nadhim Zahawi

- Hansard -

Copy Link

-

They will be able to draw on all the experience, culture and, of course, resources of Government to be able to do their job properly, I assure the right hon. Member of that.

The report sets out a fear, as we have heard elsewhere, that without a definition of national security in the Bill, interventions under the NSI regime will be politicised. I wholeheartedly agree that it is crucial for the success of the regime that decisions made are not political but rather technocratic, dispassionate and well judged. I repeat the words of my right hon. Friend the Member for Reading West (Alok Sharma), the former Business Secretary, who on Second Reading assured the House that:

“The Government will not be able to use these powers to intervene in business transactions for broader economic or public interest reasons, and we will not seek to interfere in deals on political grounds.”—[Official Report, 17 November 2020; Vol. 684, c. 210.]

Indeed, if the Secretary of State took into account political factors outside the remit of national security, the decision could not be upheld on judicial review. It is with this in mind, and our focus on protecting foreign direct investment, which so many colleagues are concerned about, especially as we come out of the covid challenge, that politicised decisions will not be possible under the NSI regime. I hope right hon. and hon. Members feel I have sufficiently explained the Government’s approach. We have sought to deliver what the Foreign Affairs Committee and the Opposition recommend.

Nadhim Zahawi

- Hansard -

Copy Link

-

As colleagues have said, the Bill has been a long time in gestation, from 2017 to the 2018 consultation and White Paper and now today. We look at what other countries do, and I think we have reached a proportionate position. Of course, as I say, the Secretary of State’s statement sets out exactly how he would assess the risks to national security. I hope I have addressed that.

My final point of reassurance is that there will be further scrutiny on this point. As I explained in Committee, the statement provided for by clause 3 will go out to full public consultation prior to being laid before Parliament, and the Government will listen carefully to any proposals for further detail.

Amendments 1, 2, 3 and 6 broadly seek to ensure that the scope of the regime as a whole is right, that mandatory notification covers the right sectors and that both the statement and the notifiable acquisition regulations are reviewed within a year. Amendment 1 would require notifiable acquisition regulations to be reviewed within a year of having been made, and once every five years thereafter. It is right that the Secretary of State keeps a constant watch on these regulations. Indeed, it is vital that he has the flexibility to reassess and, if needed, seek to update the regulations at any time. The nature of his responsibilities under the regime creates sufficient incentive for this regular review.

Amendment 2 would, in effect, introduce two further trigger events to the regime. It would mean that a person becoming a major debt holder would count as a person gaining control of a qualifying entity. The amendment would also mean that a person becoming a major supplier to an entity counted as a person gaining control of a qualifying entity.

We on the Government Benches believe that access to finance is crucial for so many small businesses and large businesses to grow and succeed. They will often take out loans secured against the very businesses and assets that they have fought so hard to build; I did just that when I started YouGov. That is why the Bill allows the Secretary of State to scrutinise acquisitions of control that take place where lenders exercise rights over such collateral, but the Government do not consider that the provision of loans and finance is automatically a national security issue. Indeed, it is part of a healthy business ecosystem that enables businesses to flourish in this country.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for my right hon. Friend’s intervention. What I was saying is that there are no restrictions. His Committee will be able to invite the Secretary of State to give evidence to it, and it will also be able to ask for further information, which the unit will be able to provide.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to the right hon. Gentleman for his intervention. Let me repeat again: there are no restrictions on the Committee requesting further information from the unit or from the Secretary of State.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to my right hon. Friend for his intervention and his powerful argument, but I just repeat that there are no restrictions on his Committee requesting that information.

Nadhim Zahawi

- Hansard -

Copy Link

-

I will not give way. There is a lot to get through and time is short.

The Government will more generally monitor the operation of the regime and regularly review the contents of the annual reports, including in relation to academic research, spin-off enterprise or SMEs, and we will pay close attention to the resourcing and the timelines of the regime.

If, during any financial year, the assistance given under clause 30 totals £100 million or more, the Bill requires the Secretary of State to lay a report of the amount before the House. Requiring him to lay what would likely be a very similar report for every calendar year as well as for every financial year, which is in amendment 4, appears to be excessive in our view. He would likely have to give Parliament two very similar reports only a few months apart.

On amendment 5, I can reassure the House that, under clause 54, the Secretary of State would be subject to public law duties when deciding whether to share information with an overseas public authority. That includes a requirement to take all relevant considerations into account in making decisions. These are therefore considerations that the Secretary of State would already need to take into account in order to comply with public law duties.

Moving on to new clause 6, I want to be clear that we do not expect the regime to disproportionately affect SMEs, although we will of course closely monitor its impact. The Government have been happy to provide support to businesses both large and small through the contact address available on gov.uk. Furthermore, the factsheets make it clear what the measures in the proposed legislation are and to whom they apply, so there is real clarity on this. It would therefore not be necessary to provide the grace period for SMEs proposed under new clause 3 and neither would it be appropriate. Notifiable acquisitions by SMEs may well present national security concerns and this proposed new clause would, I am afraid, create a substantial loophole.

To conclude, although I am very grateful for the constructive and collegiate engagement from hon. and right hon. Members across the House, for the reasons that I have mentioned I cannot accept the amendments and new clauses tabled for this debate and therefore hope that they will agree to withdraw them.

The Parliamentary Under-Secretary of State for Health and Social Care (Nadhim Zahawi)

- Hansard -

Copy Link

-

With permission, Madam Deputy Speaker, I would like to make a statement on the covid-19 vaccine delivery plan. The plan, published today, sets out the strategies that underpin the development, manufacture and deployment of our vaccines against covid-19. It represents a staging post in our national mission to vaccinate against the coronavirus, and a culmination of many months of hard work from the NHS, our armed forces, Public Health England, and every level of local government in our Union. There are many miles to go on this journey, but, armed with this plan, our direction of travel is clear.

We should be buoyed by the progress that we are already making. As of today, in England, 2.33 million vaccinations have been given, with 1.96 million receiving their first dose and 374,613 having already received both doses. We are on track to deliver our commitment of offering a first vaccine to everyone in the most vulnerable groups by the middle of next month. These are groups, it is worth reminding ourselves, that account for more than four out of every five fatalities from the covid virus, or some 88% of deaths. But of course this is a delivery plan for everyone—a plan that will see us vaccinate all adults by the autumn in what is the largest programme of vaccination of its kind in British history.

The UK vaccines delivery plan sets out how we can achieve that noble, necessary and urgent goal. The plan rests on four key pillars: supply, prioritisation, places and people. On supply, our approach to vaccines has been to move fast and to move early. We had already been heavily investing in the development of new vaccines since 2016, including funding a vaccine against another coronavirus: middle east respiratory syndrome. At the start of this year, this technology was rapidly repurposed to develop a vaccine for covid-19, and in April we provided £20 million of further funding so that the Oxford clinical trials could commence immediately. Today, we are the first country to buy, authorise and use that vaccine.

Also in April, we established the UK Government’s Vaccine Task Force, or VTF for short, and since then it has worked relentlessly to build a wide portfolio of different types of vaccine, signing early deals with the most promising prospects. It is a strategy that has really paid off. As of today, we have secured access to 367 million doses from seven vaccine developers with four different vaccine types, including the Pfizer-BioNTech vaccine, which we were also the first in the world to buy, authorise and use. The VTF has also worked on our homegrown manufacturing capability, including what is referred to as the “fill and finish” process, in collaboration with Wockhardt in Wrexham. Anticipating a potential global shortage early on, we reserved manufacturing capacity to allow for the supply of multiple vaccines to the United Kingdom. Like many capabilities in this pandemic, it is one that we have never had before, but one that we can draw on today. So much of that critical work undertaken early has placed us in a strong position for the weeks and months ahead.

The second pillar of our plan is prioritisation. As I set out earlier, essential work to protect those at the greatest clinical risk is already well under way. The basic principle that sits behind all of this is to save as many lives as possible as quickly as possible. In addition, we are working at speed to protect staff in our health and social care system. All four UK chief medical officers agree with the recommendation of the Joint Committee on Vaccination and Immunisation to prioritise the first doses for as many people on the priority list as possible and administer second doses towards the end of the recommended vaccine dosing schedule of 12 weeks. That step will ensure the protection of the greatest number of at-risk people in the shortest possible time.

The third pillar of our plan is places. As of yesterday, across the United Kingdom, we have more than 2,700 vaccination sites up and running. There are three types of site. First, we have large vaccination centres that use big venues such as football stadiums; we saw many of those launched today. At these, people will be able to get appointments using our national booking service. The second type is our hospital hubs, working with NHS trusts across the country. The third is our local vaccination services, which are made up of sites led by GPs working in partnership with primary care trusts and, importantly, with community pharmacists.

This mix of different types of site offers the flexibility that we need to reach many different and diverse groups and, importantly, to be able to target as accurately as we can. By the end of January, everyone will be within 10 miles of a vaccination site. In a small number of highly rural areas, the vaccination centre will be a mobile unit. It bears repeating that, when it is their turn, we want as many people as possible to take up the offer of a vaccine against covid-19.

The fourth and final pillar is, of course, our people. I am grateful to the many thousands who have joined this mission—this national mission. We now have a workforce of some 80,000 people ready to be deployed across the country. This includes staff currently working within the NHS of course, but also volunteers through the NHS Bring Back Staff scheme, such as St John Ambulance personnel, independent nurses and occupational health service providers. There are similar schemes across the devolved Administrations.

Trained vaccinators, non-clinical support staff such as stewards, first aiders, administrators and logistics support will also play their part. We are also drawing on the expertise of our UK armed forces, whose operational techniques—brought to life by Brigadier Phil Prosser at the press conference with the Prime Minister a few days ago—have been tried and tested in some of the toughest conditions imaginable. I am sure the whole House will join me in thanking everyone who has played their part in getting us to this point, and all those who will play an important role in the weeks and months ahead.

We recognise that transparency about our vaccine plan will be central to maintaining public trust, and we are committed to publishing clear and simple updates. Since 24 December, we have published weekly UK-wide data on the total number of vaccinations and the breakdown of over and under-80s for England. From today, we are publishing daily data for England showing the total number vaccinated to date. The first daily publication was this afternoon. From Thursday, and then weekly, NHS England will publish a more detailed breakdown of vaccinations in England, including by region.

This continues to be a difficult time for our country, for our NHS and for everyone as we continue to live under tough restrictions, but we have always known that a vaccine would be our best way out of this evil pandemic, and that is the road we are now taking. We are under no illusion as to the scale of the challenge ahead and the distance we still have to travel. In more normal times, the largest vaccination programme in British history would be an epic feat, but against the backdrop of a global pandemic and a new, more transmissible variant, it is a huge challenge. With this House and indeed the whole nation behind this national mission, I have every confidence that it will be a national success. I commend this statement to the House.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for the hon. Member’s backing and support. He asks a number of important questions, and I will attempt to answer them now. Suffice it to say that it would be sensible for us to recognise that test and trace now delivers 85% of those who are tested positive in terms of identifying their direct contacts and the indirect contacts at between 92% and 96%. Over 5 million people have been tested and isolated and are therefore not transmitting or spreading this virus, and 55 million people have been tested. That is a pretty major undertaking, with capacity now touching 770,000 and tests running at about 600,000 a day. From a standing start of about 2,000 a day back in March, that is a pretty remarkable achievement for NHS test and trace.

The hon. Gentleman asked about 24-hour provision. There are two priorities for the NHS, and we have looked really long and hard at this. Priority No. 1 is obviously to target very closely those four most vulnerable categories. Priority No. 2 is to try to get a vaccination to them as quickly as possible, which is about throughput. This is linked because if we were to go to a 24-hour regime, it would be much harder to target the vaccine at those four cohorts. Obviously, when we have limited vaccine volume, we do not want staff standing around waiting for people in centres that are open 24 hours. Also, many of those people are over 80, and we are going into care homes to vaccinate the residents of those homes. The decision to go from 8 to 8 was made because we want to ensure that there is an even spread and very close targeting.

That is linked to throughput—how many vaccinations can we get into people’s arms as quickly as possible? We do not want vaccines sitting in fridges or on shelves. That goes to the hon. Gentleman’s question on the 24 hours, but also the pharmacy question. All the 200 pharmacies that we are operationalising can do 1,000-plus vaccinations a week, so the focus in phase 1, certainly with the first four categories—and, I think, with the total nine categories—is very much on targeting and throughput. The 2,700 sites are the best way that we can target that. Obviously, primary care is very good at identifying those who are most vulnerable or over 80 and, of course, getting into care homes, hence why the NHS plan and the plan we have published today are very much based around those priorities.

As we enter phase 2, where we begin to want to vaccinate as many adults as quickly as possible, we want convenience of course. We want to be able to go into many more pharmacies, so people can walk to their local pharmacy, or GP, and get their jab, when we have limitless volumes of vaccines. We have clearly now got that optioned and it will come through in the weeks and months ahead. That is the reason for that. The hon. Gentleman is absolutely right: the limiting factor continues at this stage to be vaccine volumes. The NHS has built an infrastructure that can deploy the vaccine as quickly as possible, but it is vaccine volumes that will change. With any new manufacturing process, especially one where we are dealing with quite a complex process—it is a biological compound that we are producing—it tends to be lumpy at the start, but it very quickly stabilises and becomes much more even. We are beginning to see that, which is good news.

We are absolutely committed to making sure the health and social care workforce are vaccinated as quickly as possible, and of course we are committed to making sure the residents of care homes are vaccinated by the end of this month—January. I reaffirm that commitment to the hon. Gentleman.

I think the hon. Gentleman’s final question was on data. I am glad that he agrees that it is important, because the Prime Minister’s absolute instruction to us as a team is that we have to make sure we publish as much data as possible as quickly as possible, hence why we have moved to a rhythm of daily data and on the Thursday more detailed publication, which will have regional breakdowns. The NHS is committed as it builds up more data to publish more and more. The nation expects, and rightly wants to see, the speed and the targeting that we are delivering, but I am confident that the NHS has a solid plan. We have the volunteers and the Army—two great institutions of this country—delivering this campaign and with the support of Her Majesty’s Opposition I am sure we will do this.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful for my right hon. Friend’s compliment and this is only the start. I hope that, as we progress in the weeks and months to come, the focus and the rate of output will continue to rise.

My right hon. Friend raises an important point around the critical workforce for the economy, like teachers. The Joint Committee on Vaccination and Immunisation looked at all these issues and has come out very clearly in favour of us vaccinating the nine cohorts that are most vulnerable to dying from covid-19, hence why that is absolutely our focus.

We are absolutely committed to making sure that people get two doses, so if they have received their Pfizer first dose, they will get their Pfizer second dose within 12 weeks of the first dose. Similarly, if they have had their AstraZeneca first dose, they will get their AstraZeneca second dose within 12 weeks. So those people whom we will begin to reach in March, where we have to deliver their second dose, will absolutely get their second dose. But to my right hon. Friend’s point, the more vaccine volumes that will come, and we have tens of millions that will come through beyond February and into March, the faster we can begin to protect those nine categories in phase 1. The moment we have done that, then it is absolutely right that we should begin to look at categories like teachers and police officers—those who may be exposed in their workplace to the risks of this virus.

Of course, it is worth reminding the House that it is two weeks after the first dose, and three weeks after the first dose with AstraZeneca, that people begin to get that protection, not the moment they are jabbed, so there is that lag time as well. But my right hon. Friend’s point is well made: we need to make sure, as we protect greater and greater numbers of people in those nine categories, that we then move very quickly to the next dose.

Nadhim Zahawi

- Hansard -

Copy Link

-

There is a lot to unpack there; let me try to take the points in reverse. We can guarantee that those who have had their Pfizer vaccine will get their booster within the prescribed period of up to 12 weeks. The hon. Lady asked about those who have had a second jab already. Information went out to primary care networks and hospital hubs, saying that those who have an appointment up to 4 January should be able to have their appointment honoured. Beyond that, they have been working very closely with the NHS England team centrally, which we have been supporting with resources and actually phoning to postpone those appointments further; hence why we have protected many more people.

It is worth reminding the House that for every 250 people from the most vulnerable cohorts that we protect, we save a life. For every 20 people in care homes that we vaccinate, we save a life. The focus is therefore now very much on care homes. We began with the Pfizer vaccine into care homes. Of course, last week—on 4 January—we started to roll out the AstraZeneca vaccine, which is much easier to administer into care homes, especially for the roving teams. It had to spend two days in hospitals before it was released to primary care networks, but the moment it was released, it went into care homes and now some areas in England. We have about 10,000 care homes where we have to vaccinate residents and, of course, those who look after them. Some have done their care homes already; others are beginning to do the same thing. All will be done by the end of the month.

The hon. Lady talked about people having to travel long distances. I mentioned in my opening statement about the strategy that there will be 2,700 vaccination sites. I think she may have been confused about the figure of 1,200, which is the number of primary care networks, hospital hubs and large vaccination centres, but there will be 2,700 vaccination sites. By the end of the month, no one will be more than 10 miles away from a vaccination site.

Nadhim Zahawi

- Hansard -

Copy Link

-

My hon. Friend’s constituents will be contacted, either by their primary care network or by letter from the national booking service. They do not have to go to the national vaccination centre if that is inconvenient; they will be able to get their vaccination through their primary care network or the hospital hubs. I am very happy to take those particular two cases offline, look into them and give him some more details.

Nadhim Zahawi

- Hansard -

Copy Link

-

The hon. Lady asks an important question. In any manufacturing process—especially a new one—it is always lumpier at the beginning, and there are more challenges. There are a number of tests done by both the manufacturer and the regulator; the batch testing at the end of the process is done by the regulator, to make sure that the batches meet the very high standards that we have in the United Kingdom. That will begin to become much smoother and stabilise, and we have a clear line of sight through to the end of February, hence why we are confident that we can meet the target of offering a vaccine to the top four most vulnerable cohorts on the list of nine from the JCVI by the middle of February.

We thank the hon. Lady’s local GPs, but it is important for them to remember that the central team that is doing the distribution is running at about 98.5% accuracy at the moment, which means that 1.5% of deliveries are not as we would like them to be. We will get better at that. As Brigadier Prosser said, this is like standing up a supermarket chain in a month and then growing it by 20% every couple of weeks. It will get better. The focus of the central team is to try to give primary care networks —GPs like hers—as much time and notice as possible, so that they can plan ahead and get the four cohorts in for their jabs. It is always difficult at the outset, but it gets better by the day and will do in the weeks ahead.

Nadhim Zahawi

- Hansard -

Copy Link

-

I absolutely join my hon. Friend in congratulating and thanking the heroes of the NHS and the volunteers in Telford and Wrekin and Shropshire for vaccinating 15,000 people—15,000 of the most vulnerable people to covid who, in a couple of weeks’ time, will have that protection. He is right, I can confirm, that anyone receiving a letter where it is inappropriate or not possible for them to travel that distance to a national vaccination centre does not have to do so. They will be able to be vaccinated in their primary care network at a time and place that is convenient to them. With the national vaccination centres—seven went live today, and there will be more next week, more the week after and 50 in total by the end of the month—we are trying to effectively add to the throughput that I described earlier.

Nadhim Zahawi

- Hansard -

Copy Link

-

The people of Strangford will be pleased to hear that the hon. Member’s mother has got her first a dose of the vaccine. This is an important message to send to the whole country: if you are called up and have an appointment to get the vaccine, please turn up. This vaccine can protect your life. It can protect somebody else’s life. It is a shame to not turn up if you have booked an appointment. The NHS in England has made sure that the hospital hubs and primary care networks that have been vaccinating, and now the national vaccination centres, have on speed dial the care home workers and those on the frontline of the battle against covid who are in the JCVI’s top four cohorts, so that they can get them in as quickly as possible and not a single dose is wasted.

Nadhim Zahawi

- Hansard -

Copy Link

-

I think I dealt with the question of teachers earlier, which is incredibly important. Phase one is to focus on those who are most vulnerable to dying from this disease. As soon as we get through that to phase two, teachers and other frontline services, including police officers and others, will be absolutely uppermost in our minds and those of the Joint Committee on Vaccination and Immunisation, which helps us with that prioritisation.

My right hon. Friend is absolutely right to raise the issue of vaccine supply, and I know that her local vaccination service has done a tremendous job. There was a slight hiccup, if I can describe it as that, in making sure that they were recognised as six primary networks in the system. We rectified that, and I assure her that the volumes, certainly those of which I have line of sight, will mean that the service will receive plenty of vaccines to hit that target by mid-February of offering the top four cohorts the opportunity of the vaccine.

Nadhim Zahawi

- Hansard -

Copy Link

-

I think I shared the statistic with the House earlier that for every 20 residents of care homes that we vaccinate, we save a life. They are absolutely our priority. I give the hon. Lady this pledge: we will vaccinate or offer to vaccinate all residents of care homes by the end of the month. There are 10,000 care homes in England. Some areas of the country have already vaccinated all their care home residents. Others are beginning to. We will make sure that residents of care homes will by the end of this month be offered the opportunity of a vaccine.

Nadhim Zahawi

- Hansard -

Copy Link

-

Information, information, information. I am working across Government to make sure that we communicate the benefits, both in terms of protecting the individual, but also in protecting the communities people come from. Working with black, Asian and minority ethnic communities is incredibly important as part of the overall strategy to focus our attention to make sure all those communities come forward, especially those who work in our care homes and care for residents. Many of those workers are from BAME communities. The more that they see people like themselves taking the vaccine and getting protected, the more effective our strategy is to deliver that protection to those communities.

Nadhim Zahawi

- Hansard -

Copy Link

-

The hon. Lady makes a really important point. I pay tribute to the right hon. Member for Tottenham (Mr Lammy), who reached out to me with his concerns for his community. Sadly, I see among the community that my wife and I come from that there is a lot of disinformation, and not only on social media. There is the very clever and, I should say, evil use of platforms such as WhatsApp to share videos that scare people into not having the vaccine.

The hon. Lady is right that local government and local public health leaders have a central role to play. We are engaging with them and, of course, making sure that local leaders throughout the United Kingdom are telling the story. She is right that the most effective way is for people to see someone like them taking the vaccine and being protected. We are doing that as well.

Nadhim Zahawi

- Hansard -

Copy Link

-

My hon. Friend raises an important point. I commit to looking specifically at the point she raises. The NHS in England has done an incredible job, but of course some teams have outperformed others. We have to learn from the best and make sure we share that knowledge. If some teams need additional resource and help, we will do that. That is why we have the additional 80,000 people in the programme who are ready to help and ready to make sure we get the jabs into the arms of the most vulnerable people.

Nadhim Zahawi

- Hansard -

Copy Link

-

The hon. Lady is right to highlight the issue of distance. No one in her constituency or anywhere else in England will be more than 10 miles away from a vaccination site.

Nadhim Zahawi

- Hansard -

Copy Link

-

My hon. Friend will know that I have engaged with colleagues to dig deep into the issues their constituents may have with the vaccination programme. I am very happy to look at any cases she has. Through the combination of standing up hospitals, the primary care networks supported by community pharmacies and now the national vaccination centres, all residents within the four cohorts should be captured by the primary care services that know their communities really well. In case they are not, we are also engaging heavily with local government. One of the lessons of test and trace is to ensure that we engage with local government, because it knows its residents really well.

Nadhim Zahawi

- Hansard -

Copy Link

-

The head of NHS England, Simon Stevens, was before the Public Accounts Committee today and I am sure that the hon. Lady will look at his answers. Suffice it to say that the Chancellor has made £6 billion available for the NHS family to make sure we deliver and deploy as fast as we can to the most vulnerable cohorts in our country.

Nadhim Zahawi

- Hansard -

Copy Link

-

Absolutely. We must ensure that his residents are within 10 miles of a vaccination site at the end of this month and as early as possible to get vaccinating. He is a great champion of his constituents, and I am happy to look at any specifics he may have, take those offline and come back to him.

Nadhim Zahawi

- Hansard -

Copy Link

-

It is great to see the hon. Member looking fit and well; I wish him all the very best. He is right to say that we must ensure that every part of the country meets that target, offering those four cohorts the opportunity of a vaccine. We are looking to ensure that we publish more granular data—regional data—so that we can see which areas are not keeping up the pace and therefore direct resources to them, so that by mid-February they have made that offer.

Nadhim Zahawi

- Hansard -

Copy Link

-

We work closely with the Welsh, Scottish and Northern Irish Governments on the programme and ensure that we deliver the vaccine volumes to them. Although we do not publish the exact quantities of vaccine for a variety of reasons—including that the whole world is looking to get more volume of vaccines and we do not want to disadvantage ourselves in any way commercially—I reassure my hon. Friend that all the devolved Administrations will have enough to be able to offer those four JCVI cohorts the opportunity to be vaccinated and protected by mid-February, at least with a first dose.

Nadhim Zahawi

- Hansard -

Copy Link

-

I thank all the teachers in Vauxhall and the rest of the country for the work they are doing on online education as well as teaching children from the most vulnerable families and the children of our NHS and social care staff on the frontline. The hon. Member is right to highlight the issue. Some teachers—those who are clinically vulnerable, for example—will be captured in the nine cohorts set out for us by the Joint Committee on Vaccination and Immunisation, as will those in the right age groups in categories one to nine. I give her the commitment that as soon as we are through phase one, the priority absolutely will be to ensure that those who are critical to the functioning of the future of our country—the future generations to come—are prioritised.

Nadhim Zahawi

- Hansard -

Copy Link

-

I absolutely share my hon. Friend’s concern. I give her that commitment. The team at NHS England is working and focusing on giving as much time and notice as possible to primary care and hospitals on when they get deliveries, so they can make those appointments and keep vaccinating those who are most vulnerable. That is exactly its priority at the moment.

Nadhim Zahawi

- Hansard -

Copy Link

-

First of all, with respect, that is inaccurate. Community pharmacies are already part of the primary care networks that are delivering the vaccines. I have also made very clear in the strategy that there will be 200 community and independent pharmacies as part of the vaccination programme in phase one, where we need that volume and throughput. The community pharmacies that can do 1,000 vaccinations a week are very much part of the programme and we thank them for that. As we get to the next stage, where we have vaccines in limitless volumes, it is about convenience and ramping up the number of community pharmacies that can also join in the fight against covid.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to my hon. Friend, who always asks very important practical questions. He is absolutely right to say that it has been challenging. Part of the challenge, which I think we have addressed today, is the amount of notice primary care networks and GPs have of a delivery. That will only get better as we stabilise deliveries to the warehouses and are then able to take them out into the primary care networks and hospitals. I will of course work with primary care networks and the whole of the NHS family to make sure our communications get better and better.

Nadhim Zahawi

- Hansard -

Copy Link

-

I shall take the hon. Lady’s questions in reverse. The four chief medical officers have looked at the issue of the up-to-12-week dosing and all agree that it is the right thing to do. I apologise to the people Salford for that cancellation, if that is what happened yesterday. We have touched on this, but part of the issue has been the lumpiness in the deliveries in the early days, which will begin to become much smoother. The NHS central team, with Brigadier Prosser and the 101 Logistic Brigade, are absolutely focused on making sure that we give as much notice as possible to primary care networks so that they can plan ahead, and that will only get better and better as we smooth out the delivery process from manufacturer into warehouse.

Nadhim Zahawi

- Hansard -

Copy Link

-

If people receive a letter from the national booking centre and it is more convenient for them to take up that appointment than to call and make an appointment, they should get their vaccination done through the national booking centre. If that is inconvenient, they can absolutely wait and the primary care network will contact them and give them an appointment to make sure that they are vaccinated. Our absolute pledge is to make sure that the four categories that are most vulnerable to coronavirus are offered a vaccine by mid-February.

Nadhim Zahawi

- Hansard -

Copy Link

-

Scottish care homes tend to be much larger in profile than the 10,000 homes in England. We are very much focused on making sure that we vaccinate all care home residents by the end of January. We are working with the four CMOs, who are working very closely together, to make sure that that particular cohort is protected. As I mentioned earlier, if we protect 20 residents, we save a life, and that is what we do.

Nadhim Zahawi

- Hansard -

Copy Link

-

I commend the Israeli Government and health service for a stellar job in vaccinating their most vulnerable communities. We have a lot to learn from other countries, including the throughput—the speed at which they manage to vaccinate—which is something from which we can all learn so that we can improve our output. NHS England and the teams on the frontline have been doing a tremendous job and is worth us all thinking about that: we stand on the shoulders of real heroes.

Nadhim Zahawi

- Hansard -

Copy Link

-

My right hon. and learned Friend is absolutely right. I can give him the reassurance that anyone who has had their appointment cancelled will get that appointment reinstated and will get their vaccine. Our absolute commitment is to make sure that those four most vulnerable cohorts have the offer of a vaccine by the middle of February.

Nadhim Zahawi

- Hansard -

Copy Link

-

The Lady is absolutely right to highlight that cohort, some of whom will be picked up in category 4 and some of whom will be picked up in category 6—this will include the people who look after them.

Nadhim Zahawi

- Hansard -

Copy Link

-

My hon. Friend is absolutely right; the primary care networks are best suited to focusing on that and delivering that vaccination, which will protect those who are most vulnerable from dying from covid-19.

Nadhim Zahawi

- Hansard -

Copy Link

-

It is not our capacity, but the manufacturers’; AstraZeneca produces the Oxford vaccine, and Pfizer-BioNTech produce their vaccine, and Moderna’s is now also approved and in process. There are a number of processes throughout the manufacturing process. When we go from the bulk vaccine into fill and finish, there is a period of time and a sterility test the vaccines have to go through. Then there is batch testing by both the manufacturer and the regulator. All of that gets better and better every single day. It is a new manufacturing process. Oxford-AstraZeneca are delivering 100 million vaccines, which is what we have bought from them, and we have bought 40 million from Pfizer. We will have millions of vaccines in the weeks and months to come. We will meet our target of mid February for delivering the opportunity of a vaccine to the four cohorts most vulnerable to covid.

The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (Nadhim Zahawi)

- Hansard -

Copy Link

-

It is slightly unfortunate, Sir David, that the shadow Minister, the hon. Member for Ellesmere Port and Neston (Justin Madders), asked a lot of questions, because he took up a lot of time. Nevertheless, I will attempt to answer as many colleagues’ questions as possible.

Before setting out details of the plan for vaccination, I thank the hon. Member for Gower (Tonia Antoniazzi) for the incredible passion with which she spoke. I apologise that I was not in the room for her speech—I was in the main Chamber, as she will know—but it has always been our strategy to suppress the coronavirus until a vaccine can make us all safe, because we know ultimately that vaccines are our way out of this terrible pandemic.

This afternoon we launched our complete vaccine deployment plan, the culmination of months of preparation and hard work by the NHS, the armed forces—the hon. Member for North Antrim (Ian Paisley) mentioned the armed forces, and they are embedded in the deployment programme—and, of course, local and regional government at every level. The sooner we can reduce mortality from this pernicious disease and bring an end to that human suffering, the better.

It is worth reminding ourselves of just what that suffering looks like. Sadly, yesterday, 563 deaths were reported. The average number of deaths per day over the past week has been 909, and behind every statistic is a person—a father, a mother, a sister, a daughter, a grandfather or a grandmother—with family and friends. We must never lose sight of that.

In the light of the petition that we are discussing and, of course, the time, I will reflect on the basic principles that sit behind our prioritisation and our strategy. Yes, we want to minimise disruption for pupils, parents and teachers; yes, we want to stop the NHS being overwhelmed, and yes, we want to protect UK jobs and businesses as much as we possibly can, but fundamentally it is about saving lives, and operationally it is about saving as many lives as possible, as quickly as possible.

I defy anyone to provide more powerful grounds for action in order to achieve that. We are following the science and we are vaccinating, according to the prioritisation by the Joint Committee on Vaccination and Immunisation, which recommended rapid immunisation of our most vulnerable groups. It is worth reminding colleagues, as my hon. Friend the Member for Winchester (Steve Brine) did, about the first four categories, for whom we absolutely are focused on making sure they have the opportunity of a first dose to protect them by mid-February across all four nations.

I know the hon. Member for Cardiff South and Penarth (Stephen Doughty) and others are concerned about supplies, and he has contacted me about that. I can reassure him that, having spoken to my counterparts in the devolved Administrations that, while the supply lines have been lumpy—in any manufacturing process, especially one so complex as a novel vaccine that is a biological compound, it is always difficult at the outset, but they very quickly stabilise—we have clear line of sight of deliveries all the way through until the end of February, hence we are able to make the pledge that we will be able to deploy.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am conscious of time, and I want to get through quite a lot; I will be happy to take the hon. Lady’s intervention if I can.

Obviously, if a teacher or a school or childcare worker falls within one of those cohorts, they will be contacted by the NHS at the appropriate time to receive the vaccine, but the importance of starting with our most vulnerable groups cannot be overstated. There is no evidence that teachers or school or childcare workers are at higher risk of mortality. That is the thing: we are protecting against death in this first phase, and our most vulnerable groups account for 88% of mortality; I think my hon. Friend the Member for Winchester gave us that figure earlier. We can safeguard against 88% of mortality if we vaccinate those top four groups, but of course I understand the sentiment behind this petition.

Nadhim Zahawi

- Hansard -

Copy Link

-

Schools, as the hon. Member for Westmorland and Lonsdale (Tim Farron) reminded us, are open. Primary and secondary schools are open, delivering both online education and education in school for the most vulnerable children and the children of NHS and social care workers, who look after the people who are most vulnerable and whom we are trying to protect from dying. I understand the sentiment behind the petition and pay tribute to the vital work that teachers in schools and childcare workers do to see us through this difficult time. However, I believe that our strategy of putting the most vulnerable first is the right one, morally, ethically and practically, but I recognise that even with such brilliant work in full swing the next few weeks will be difficult, especially in education settings.

We have always sought to keep schools open, and said that they would be the very last things to close, but the challenges posed by the new variant and the more than doubling of transmissibility mean that we have had to take some difficult decisions. I am confident that as our vaccination programme bears fruit we can begin slowly to move out of lockdown. The Prime Minister has promised that schools will be the very first places to reopen, working on the principle of last in, first out. The hon. Member for Gower asked about testing, and it will continue to play a vital role in getting children back into the classroom as soon as possible.

In the time available to me, I want briefly to turn to some of the questions asked by colleagues. The hon. Member for Twickenham (Munira Wilson) rightly reminded us that we do not yet know whether the vaccines have an impact on transmissibility—but they obviously offer protection, in terms of both immunity and protection from severe infection. That is why we are focusing on the most vulnerable people. Of course she was right to highlight the issue of young adults with special educational needs. Some of those will be picked up in category 4, but many will be picked up in category 6 of the top nine categories.

I was not in the Chamber when the hon. Member for Leeds North West (Alex Sobel) rightly asked whether hospices are included. The shadow Minister, the hon. Member for Ellesmere Port and Neston, also asked about that. Hospices are absolutely included in the cohorts, and we are focusing on making sure that they are protected. Many Members, including my hon. Friends the Members for Montgomeryshire (Craig Williams) and for Winchester, and the hon. Members for Cardiff South and Penarth and for Westmorland and Lonsdale, asked about data. Data is our ally in this endeavour, in the Prime Minister’s view and in my view. That is why he has insisted on daily data release, so that the nation can see the progress that we are making in protecting the most vulnerable people from covid. We will continue to publish daily data. On Thursdays we will publish more detailed regional data, and my absolute commitment to the House is as much data as the NHS feel is robust that we can publish. We all reference our own experiences in life but the best way to learn, in my view, is to learn from different teams. Not everyone can give 1,000 vaccinations a day, as some primary care networks have, but we learn from them and we try to put support into other teams, to enable them to do that. [Interruption.]

I am conscious that the debate ends at 7.30 and I think I have to give the hon. Member for Gower at least a minute to respond, so I will wrap up there. I apologise to the hon. Member for Westmorland and Lonsdale, who wanted to intervene, and I would have loved to take his intervention, but I am happy to write to him if he emails me with any other queries. I shall give the hon. Lady the last word.

The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (Nadhim Zahawi)

- Hansard -

Copy Link

-

My Department continues to deliver a wide range of measures to support UK businesses. We have extended our loan schemes, which have already delivered more than £65 billion of finance, until the end of January.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to my hon. Friend for her excellent question. The 10-point plan will build on the nearly half a million green jobs that already exist in the UK economy, supporting up to 250,000 further high-skilled jobs. The House will be interested to know that we are talking about 60,000 in offshore wind, 10,000 or more in nuclear, 50,000 in green and comfortable homes, 8,000 in hydrogen, 53,000 in carbon capture utilisation and storage and 40,000 in accelerating the shift to zero-emission vehicles.

Nadhim Zahawi

- Hansard -

Copy Link

-

I absolutely agree with my hon. Friend; now more than ever it is vital that we continue to help our local economy by supporting our town centres and high streets. That is why we have delivered one of the most generous comprehensive packages of support, with a total financial package of £200 billion.

Nadhim Zahawi

- Hansard -

Copy Link

-

The recent Small Business Saturday event meant that the spend from the Great British public rose to £1.1 billion this year, which is a 38% rise on last year. The Government will continue to champion small businesses, through our unprecedented support schemes, as they begin to recover from the impact of covid-19. As the Secretary of State has just reminded me, the spend is not £200 billion—it is £280 billion of support for small business.

Nadhim Zahawi

- Hansard -

Copy Link

-

As a fellow engineer, the hon. Lady will know that the Made Smarter initiative has been a tremendous pilot in the north-west. We recently announced a further expansion, with £300 million—£147 million coming from the Government and the balance coming from the private sector—to support the adoption of technology into manufacturing. I hope the hon. Lady will continue to support Government initiatives such as Made Smarter.

The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (Nadhim Zahawi)

- Hansard -

Copy Link

-

Businesses in tier 2 that are required to close can access payments of up to £1,500 per 14 days of closure. We are giving additional financial support of £1.1 billion to local authorities to support other businesses severely affected by restrictions even though open.

Nadhim Zahawi

- Hansard -

Copy Link

-

I recognise that the winter months will continue to be extremely tough on many businesses in my hon. Friend’s constituency, but I am confident that the grant programme that we have in place, alongside other measures like the job retention scheme and the support for the self-employed that have been so widely discussed this morning, will continue to deliver that support. An estimated 90% of small and medium-sized business premises in closed retail, hospitality and leisure sectors should, broadly, have their monthly rent covered by the business grant programme.

Nadhim Zahawi

- Hansard -

Copy Link

-

The local restrictions support grants, additional restriction grants and Christmas support payments are all available now for businesses through their local authority. I know that the Secretary of State takes these businesses very seriously. Throughout this whole process, since back in March, he made sure that all his Ministers talked to local government to make sure that we do get those payments out promptly.

The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (Nadhim Zahawi)

- Hansard -

Copy Link

-

The Government have invested approximately £1 billion through two life sciences sector deals, helping to generate significant industry investment in the UK. Last year the industry had a turnover in the UK of £80.7 billion.

Nadhim Zahawi

- Hansard -

Copy Link

-

Clearly, the UK’s relationship with the EU is subject to ongoing negotiations, but as we leave the EU the life sciences sector will be supported through the life sciences sector deals that I mentioned, and a new, innovative regulatory framework. The Medicines and Healthcare Products Regulatory Agency has proven itself globally to be one of the finest regulators in the world, and new international regulatory collaborations are on the way too.

The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (Nadhim Zahawi)

- Hansard -

Copy Link

-

It is a pleasure to serve under your chairmanship, Sir David. I congratulate my hon. Friend the Member for Carshalton and Wallington (Elliot Colburn) on his leadership of this important debate on e-petition 323442. Over 300,000 people have signed the petition, including 641 in his constituency.

I am grateful to the hon. Member for Strangford (Jim Shannon) for his very moving speech, and I am deeply saddened by the loss of his mother-in-law and the infection of his wife, other family members and friends. As the shadow Minister rightly pointed out, the hon. Member for Strangford brought home that each and every statistic is a person, with a family and people who love them very much.

I will hopefully address the excellent—as always—speech by my hon. Friend the Member for Wycombe (Mr Baker). I am grateful to the hon. Member for North Ayrshire and Arran (Patricia Gibson) both for her excellent speech and for her clear confirmation that neither the Scottish Government nor the United Kingdom Government will mandate vaccination at all. I congratulate her chief medical officer, as well as the chief medical officers in Northern Ireland and Wales, who worked together so that we could all start to vaccinate on the same day, last Tuesday. I am grateful, Sir David, for the opportunity to speak on behalf of the Government this evening.

Nadhim Zahawi

- Hansard -

Copy Link

-

I hear the hon. Gentleman; Northern Ireland was first by a few minutes.

Last week was a most important week across the United Kingdom, because we began vaccinating people against covid-19, and that, I hope, has started to turn the tide on this virus. The pandemic has forced the Government and our devolved Administrations to take steps that are truly unprecedented in peacetime. They are steps that no democratic Government would wish to take unless they were absolutely necessary. At each point in the pandemic, every decision we have taken has been with the utmost consideration for its impact on our personal freedoms. As hon. Members have brilliantly highlighted this evening, and as my hon. Friend the Member for Wycombe rightly reminded us, the petition that we are debating is a matter of great legal and ethical complexity.

Before I address some of those complexities, I will set out the facts. First, there are currently no plans to place restrictions on those who refuse to have a covid vaccination. As my hon. Friend the Member for Carshalton and Wallington reminded us, we have no plans to introduce so-called vaccine passporting. My hon. Friend the Member for Wycombe was slightly nervous about that, quite rightly, as when I did my first interview about the issue—with the BBC, I think—I was asked about some of the technological challenges and I may have mis-spoken. I was grateful to The Spectator and TalkRadio, which allowed me to explain myself.

Mandating vaccinations is discriminatory and completely wrong, and, like my hon. Friend the Member for Wycombe and others, I urge businesses listening to this debate to not even think about that. I will explain in further detail why that is the wrong thing to do. I put on record my thanks to Professor Karol Sikora, who has many hundreds of thousands of followers, who quoted me and said I eloquently dealt with the issue. We have absolutely no plans for vaccine passporting.

Secondly, cards that were issued after people got their first covid-19 vaccination have been mentioned on social media. Among other details, they contain the date of their second vaccination. That record does not constitute a so-called vaccine passport. It does mean anyone is immune. As we know, the vaccine is given as two injections, 21 days apart. The second dose is the booster dose. I am sure hon. Members will forgive me for repeating the message that patients must return as instructed for their second dose. Without the second dose, the vaccine will not be effective. That is a really important message, and I am grateful to all hon. Members who are repeating that to their constituents.

Thirdly, on completion of both vaccinations, patients will be issued with a vaccine record card, much as they are for other vaccination programmes, so there is nothing different in the way we are dealing with this vaccine. Again, that does not constitute a so-called vaccine passport; nor can it be used as a form of identification. That would be absolutely wrong. Colleagues will appreciate that the careful and accurate recording of vaccination status is an important part of a public health effort. It supports patient safety during probably the largest and most challenging vaccination programme in British history.

Fourthly, in addressing the many who signed the petition, I want to underline one key fact, which we have heard over and over again from hon. Members: vaccines work. It is really important that we send that message from this place. After clean water, they are the single greatest public health tool in the history of mankind. My hon. Friend the Member for Carshalton and Wallington reminded us of Edward Jenner. It fills me with great joy that the Jenner Institute was one of the first to stand up and say, “We can do this.” I hope that, after a rigorous study by the Medicines and Healthcare Products Regulatory Agency, the Oxford-AstraZeneca vaccine will be in place as soon as approval comes through. Obviously it is up to the regulator to deliver that.

Vaccines, as we have heard, have ended untold suffering for millions, if not billions, of people around the world. When our turn comes and our GP gets in touch, we all have a duty to heed that call. It is how we will be able to protect ourselves and the people around us—our friends and family, the people we love. Months of trials, involving thousands of people, have shown that the vaccines we are using are effective. They work. In answer to my hon. Friend the Member for Carshalton and Wallington, they have been tested on between 15,000 and 50,000 people. There were no shortcuts or quick fixes by the MHRA; it has followed exactly the same process as usual. The difference is that instead of waiting for phase 1 to finish before doing phase 2, and then phase 3, the studies were in parallel; hence we were able to develop the vaccines rapidly.

Fifthly, and equally importantly, each covid vaccine will be authorised only, as I have said, once it has met robust standards of effectiveness, safety and quality. As we have heard, vaccines authorised by our independent regulator, the MHRA, will be assessed for clinical safety and effectiveness through a robust review. The vaccine is free to everyone eligible across the UK. There is really no excuse for someone not to take it when their turn comes.

Sixthly, although we know the vaccine protects individuals, we do not yet know its precise impact on onward transmission. My hon. Friend the Member for Wycombe made that point brilliantly himself, and by quoting the Secretary of State. In answer to the hon. Member for Nottingham North (Alex Norris), we will not know where the point is that he mentioned until we scale up the vaccinations. We will continue to monitor the impact on transmission through the Test and Trace system. As my hon. Friend the Member for Wycombe said, we do know that the vaccine protects people, which is the important thing. That is why I encourage everyone to read, read and read again—or to ask, ask and ask again, to quote the hon. Member for Nottingham North.

The full impact on infection rates will not become clear until we get to those large numbers, so we are monitoring that carefully. Hon. Members will understand that without our knowing that, it would be irresponsible for anyone to declare that they are immune. The Qantas question is therefore completely wrong, because it is impossible for anyone to say that. The science does not yet support that conclusion. Even if people are vaccinated, they must continue to follow the rules where they are, and keep taking the common-sense steps that are now so familiar to us—washing our hands, covering our face and making space.

Hon. Members have raised many questions about the World Health Organisation and the required international response. The United Kingdom Government have led the way. We could do even more. Next year, the UK will take up the presidency of the G7, as the hon. Member for Nottingham North mentioned; we will need to deal with anti-vaxxers nationally and internationally. We look forward to working with many nations on that challenge.

I will turn to some of the hon. Gentleman’s other questions. On GPs and the additional 15 minutes, that was the further guidance from the MHRA after two cases in which people with a history of severe allergies had an allergic reaction to the Pfizer-BioNTech vaccine. That is why there was a change to the process. On the roll-out today to primary care networks and the question about caseloads, it is brilliant that GPs have come together with primary care networks. For example, in an area of 50,000 people and five practices, they have come together and agreed that one would lead on the vaccination while the other four continued to support the community and deal with caseloads. On his question about care home staff who continue to be prioritised, I am happy to take that offline with him if he has a particular case or details.

The petition that we have debated is of profound importance. I urge anyone who is considering refusing a covid-19 vaccination to ask and ask again. Not only is the vaccine effective and proven to be clinically safe, but the quicker we are able to vaccinate people, the quicker we can bring forward the date when we can begin to lift the oppressive restrictions that were put in place with a truly heavy heart. I came from a world of entrepreneurialism, of unleashing people’s ingenuity, energy and passion. I did not enter politics to restrict people’s freedoms, which I profoundly believe in. In the meantime, we all have our part to play. We must continue to respect the rules to ensure that the efforts succeed and can be our shared success, so that we can all have a more joyous 2021. If I do my job properly, we will all be back in this Chamber celebrating, I hope, without the restrictions that we have today.

The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (Nadhim Zahawi)

- Hansard -

Copy Link

-

Glorious.

Nadhim Zahawi

- Hansard -

Copy Link

-

I beg you indulgence, Mr Twigg: I intend to speak first to clause stand part and then to amendment 29, which was tabled by the hon. Member for Southampton, Test. Clause 53 gives the Secretary of State the power to make regulations that set out the procedure that the Secretary of State must follow when giving a notice of, or serving, an order once the Bill becomes an Act. The level of detail that these provisions will involve is most appropriately dealt with in delegated legislation. That will also allow the provisions to be modified more easily if changes are deemed appropriate—in the light of operational experience, for example. I know all colleagues will share with me the wish for the unit’s operations to be as efficient and as slick as we can make them.

Examples of notices and orders include information notices, attendance notices, interim orders, final orders or penalty notices issued by the Secretary of State for non-compliance. The clause sets out what may be included in the regulations. For example, they may include the manner in which a document must be given or served and whether it is allowed to be served electronically—for example, by email.

Amendment 29 would require the Secretary of State to make these regulations, which returns, if I may say so, to the recurring theme raised by the hon. Member for Southampton, Test, about the difference between “may” and “shall”. At the risk of becoming predictable, my thoughts here carry certain echoes of our previous discussions.

As hon. Members will know, clause 53 gives the Secretary of State the power to make regulations that will set out the procedure that must the Secretary of State must follow when giving a notice or serving an order once the Bill becomes an Act. It is an entirely laudable objective to ensure that the Secretary of State provides those affected by this regime with the right information on the operation of the regime, and it is one that I shall always support. In practice, though, the amendment is unnecessary.

Although the Secretary of State may make regulations to that effect, in practice, for the regime to function effectively, he must do so. I assure hon. Members that the Secretary of State certainly does not propose to commence the regime without first making these procedural regulations. I therefore assure the hon. Member that the amendment is not required, as he and the Government seem to be in hearty agreement on the importance of such regulation. I ask him to do the honourable thing and withdraw the amendment.

Nadhim Zahawi

- Hansard -

Copy Link

-

Passionate exchanges.

Nadhim Zahawi

- Hansard -

Copy Link

-

indicated assent.

Nadhim Zahawi

- Hansard -

Copy Link

-

With your permission, Mr Twigg, I will speak initially to clause 54 stand part and then address amendment 30, relating to clause 54. I will then turn to clause 55 stand part.

On clause 54, for this regime to function effectively, the Secretary of State needs access to the right information at the right time to make decisions with the fullest range of evidence available. All relevant information required by the Secretary of State to make a decision might not be obtainable from the parties to the acquisition, but rather might be stored by other public authorities, both in the UK and overseas. The hon. Member for Newcastle upon Tyne Central referred to the speed at which deals have changed; she mentioned Facebook and others. I agree that modern deals are structured in an increasingly complex manner and often across borders and continents. There is a need to work with allies at home and abroad to ensure that we are making well-aligned, timely and correct decisions.

Therefore, the clause provides that public authorities may disclose information to the Secretary of State for the purpose of facilitating the exercise of his functions under the Bill. Equally, it permits the Secretary of State to disclose information to UK and overseas public authorities for the purpose of facilitating his functions under the Bill, but also for a limited number of other purposes, including crime prevention and the protection of national security. I absolutely agree with those who say that businesses do not want slow decisions made by multiple public authorities working in silos. We all want to see an efficient regime in place. Businesses want public authorities that can talk to each other and give a quick and efficient answer that is right first time. Being able to share information is the first step in Government making fast and informed decisions without having to burden businesses unduly, which I know the hon. Lady cares about.

I of course recognise, though, that some hon. Members will feel uneasy about the Government being able to share potentially very sensitive information both within the UK and overseas. The clause includes a number of safeguards relating to the disclosure of information by the Secretary of State. First, the clause prohibits onward disclosure of information shared by the Secretary of State or use for an alternative purpose without his consent. Secondly, when disclosing information, the Secretary of State must consider whether the disclosure would prejudice, to an unreasonable degree, the commercial interests of any person concerned.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to the hon. Member. I hope that in my further remarks, if I can make some headway, I will be able to reassure him on those points.

Thirdly, when disclosing information to an overseas public authority, the Secretary of State must have particular regard to whether the law of the country or territory to whose authority the information is being disclosed provides protection against self-incrimination in criminal proceedings corresponding to the protection provided in the UK, and whether the matter is sufficiently serious to justify disclosure. I hope that addresses the hon. Member’s point.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful. If the drive of the hon. Member’s probing is to ensure that the Secretary of State, when he considers disclosing information to a foreign country, takes into account protecting people being caught in the regime who come from that country, I think I have just made it clear that the clause provides protection against self-incrimination in criminal proceedings corresponding to the protection provided in the United Kingdom. I hope that the hon. Member will be satisfied with that.

Finally, the disclosure is subject to data protection legislation, which provides additional safeguards in relation to the disclosure of personal data. I hope that the hon. Member for Newcastle upon Tyne Central will feel reassured that the Secretary of State may request only the information that he requires in order to exercise his function under the Bill, and that such information will be treated securely.

Amendment 30 aims to increase the scrutiny that the Secretary of State undertakes in deciding whether a person constitutes an overseas public authority for the purposes of disclosing information under clause 54. It is of course important to ensure that any person believed to be a public authority for the purposes of seeking information from, or disclosing information to, is a public authority. I am therefore pleased to reassure the hon. Lady that the Bill does that as it stands. The approach that we have taken mirrors that—I know that she does not like this—in section 243(11) of the Enterprise Act 2002, which includes a similar definition of an overseas public authority for the purposes of disclosure of specified information to overseas public authorities under the Act.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am grateful to the hon. Lady. I remind her that the legislation requires the Secretary of State to act in a quasi-judicial way, not as a political figure. I appreciate that by a normal reading, “appears” may appear unduly casual, but that is merely a question of the form of legislative drafting, which is consistent, I remind her, with previous relevant legislation.

In addition, I reassure the hon. Lady that the principles of public law apply in any case. The Secretary of State therefore needs to act reasonably in fulfilling his functions under the Bill. That includes having a reasonable basis, supported by sufficient evidence, for coming to the conclusion that a person appears to be an overseas public authority prior to disclosing information. I hope I have provided the Committee with sufficient reassurances, and I therefore hope that the Opposition will withdraw the amendment.

Nadhim Zahawi

- Hansard -

Copy Link

-

Quasi-judicial.

Nadhim Zahawi

- Hansard -

Copy Link

-

It is not a strange concept that a Minister acts in a quasi-judicial way in making such decisions.

I will now briefly turn to clause 55, which makes provision for specific restrictions in respect of information received under clause 54 from Her Majesty’s Revenue and Customs. For the regime to function effectively, the Secretary of State needs access to the right information at the right time in order to make decisions with the fullest range of evidence available. One such source of information that might be invaluable to the Secretary of State is HMRC. Although the Government expect that the Secretary of State would seek first to secure the information he needs from the parties, it is important that such information can also be provided from elsewhere in Government, if it is held there.

Clause 55 provides that where information is received by the Secretary of State from HMRC or an onward recipient pursuant to clause 54, it may not be used for purposes other than the Secretary of State’s function under the Bill, and nor may it be further disclosed without HMRC’s consent. Clause 35 provides that disclosing information in contravention of clause 55(1) is an offence, as is appropriate.

Nadhim Zahawi

- Hansard -

Copy Link

-

I am just finishing my point.

I hope that hon. Members will agree that clause 55 provides appropriately robust safeguards for the onward sharing or use of information received from HMRC for the purposes of the regime. I recommend that clauses 54 and 55 stand part of the Bill.

Nadhim Zahawi

- Hansard -

Copy Link

-

Clause 56 places a duty on the CMA to provide information and any other assistance to the Secretary of State to enable him to carry out his functions under the Bill. For this regime to function effectively, the Secretary of State needs access to the right information at the right time to make decisions with the fullest range of available evidence.

The Competition and Markets Authority, by virtue of its position as the market regulator, will naturally have access to information that could be relevant to the decisions made by the Secretary of State. Although in practice we would expect the CMA to be entirely willing to provide support to the regime, and we have worked closely with it in drafting the legislation, the clause ensures that there is no doubt in law about the duty placed on the CMA to provide any information in its possession or any other assistance in its power when directed to do so by the Secretary of State, so long as the information or assistance is reasonably required to facilitate the Secretary of State’s functions under the Bill.

I therefore anticipate that the power in the clause—mirroring section 105(5) of the Enterprise Act 2002—would, in practice, be used only rarely, given the Department’s good working relationship with the CMA. I hope the Committee will appreciate that the clause is quite simply about ensuring that the Secretary of State has access to pertinent information relevant to the decision-making process.

Nadhim Zahawi

- Hansard -

Copy Link

-

Clause 57 provides that the provisions in parts 1 to 4 of the Bill containing a duty or power to disclose or use information do not authorise a contravention of data protection legislation, as set out in the Data Protection Act 2018. In addition, the clause provides that that information may be used or disclosed only if it does not contravene parts 1 to 7, or chapter 1 of part 9, of the Investigatory Powers Act 2016, which contains provisions about conducting interception, including restrictions on use and disclosure of intercepted information. These standard provisions are included where legislation concerns the use or disclosure of information. I hope that hon. Members will therefore be content to support this standard clause as part of the legislation.

Question put and agreed to.

Clause 57 accordingly ordered to stand part of the Bill.

Clause 58

Minor and Consequential Amendments and Revocations

Question proposed, That the clause stand part of the Bill.

Nadhim Zahawi

- Hansard -

Copy Link

-

Clause 58 is purely technical in nature and inserts schedule 2 into the Bill. Schedule 2 provides for minor and consequential amendments and revocations. The Secretary of State currently has the power to intervene in qualifying mergers on national security grounds by issuing a public interest intervention notice, a special intervention notice or a European intervention notice under the Enterprise Act 2002, where the statutory requirements are met. It would clearly be unnecessary for the Secretary of State to retain these powers once the provisions of the Bill come into force. Schedule 2 therefore removes national security as a ground on which the Secretary of State may intervene under the Enterprise Act 2002. The Secretary of State will retain the powers in the Enterprise Act 2002 to intervene in qualifying mergers where these raise issues of media plurality, the stability of the UK financial system or maintaining in the UK the capability to combat and to mitigate the effects of public health emergencies.

Question put and agreed to.

Clause 58 accordingly ordered to stand part of the Bill.

Schedule 2 agreed to.

Clause 59

Overseas information disclosure

Question proposed, That the clause stand part of the Bill.

Nadhim Zahawi

- Hansard -

Copy Link

-

Clause 59 removes a restriction on the ability of the Competition and Markets Authority to co-operate with its international partners on merger cases. At the end of the transition period, the UK will no longer be part of the European Union’s competition system. The CMA will become responsible for investigating the effects on competition of larger international mergers, which were previously investigated by the European Commission. In a globalised economy, effective cross-border enforcement of competition law, which protects UK markets and consumers, relies increasingly on close international co-operation. The ability to disclose confidential information to assist an overseas authority with this enforcement activity, including in circumstances where parties have not provided their consent for the information to be disclosed, is a crucial ingredient of strong co-operation.

Moreover, the willingness of an overseas authority to disclose confidential information will often depend on whether the receiving authority can reciprocate. Any restrictions on the CMA’s ability to disclose such information could therefore inhibit the effectiveness of its international co-operation. The overseas disclosure gateway, which is set out in section 243 of the Enterprise Act 2002, provides an important mechanism for the CMA to disclose information to its overseas counterparts when consent has not been provided by relevant parties. The gateway permits disclosure for the purpose of helping an overseas authority’s enforcement activities.

However, the CMA is currently unable to use the overseas disclosure gateway to disclose information that comes to it in connection with a merger investigation. This means that the CMA is restricted from sharing certain information with its overseas counterparts that might be crucial to their investigation of a merger. This restriction presents two challenges for the UK’s competition authorities. First, it weakens the control of mergers with an international dimension that might adversely affect UK markets and consumers. Secondly, it inhibits the CMA’s ability to receive information that might be critical to its own merger investigations, because it has no ability to reciprocate. That, in turn, could also weaken its protection of UK markets and consumers. Clause 59 rectifies this by removing the restriction in the overseas disclosure gateway and allowing the CMA to use the gateway to disclose merger information to overseas public authorities.

Nadhim Zahawi

- Hansard -

Copy Link

-

The hon. Lady is quite right that it is to help the CMA.

Nadhim Zahawi

- Hansard -

Copy Link

-

It is worth respectfully reminding the hon. Lady and the Committee that this is a separate topic in the Bill that is unrelated to the NSI regime, as set out in the explanatory notes.

Nadhim Zahawi

- Hansard -

Copy Link

-

I think that is slightly unfair; it is included in page 4 of the explanatory notes.